In:
Journal of Modern Oncology, Consilium Medicum, Vol. 23, No. 2 ( 2021-08-16), p. 287-291
Abstract:
Extensive-stage small cell lung cancer (ES-SCLC) is characterized by an aggressive course, a high recurrence rate and fast progression. For a long time, the survival prognosis for the most patients suffering from this disease remained unfavorable. The situation changed with the appearance of chemoimmunotherapy in clinical practice. Chemotherapy based on durvalumab in comparison with the standard chemotherapy demonstrated the statistically and clinically significant increase in median overall survival in patients with previously untreated ES-SCLC in the CASPIAN international trial. This article deals with the case of the application of standard chemotherapy in combination with durvalumab as a first-line ES-SCLC therapy. The patient started receiving durvalumab therapy in June 2017 as a part of the CASPIAN international trial. In March 2021 the duration of therapy was 45 months, the patient had a complete regression of the disease.
Type of Medium:
Online Resource
ISSN:
1815-1442
,
1815-1434
DOI:
10.26442/18151434.2021.2.200901
Language:
Unknown
Publisher:
Consilium Medicum
Publication Date:
2021
